HUTCHMED (NASDAQ:HCM - Free Report) had its target price raised by Bank of America from $27.00 to $28.00 in a research report released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.
Other analysts have also issued reports about the stock. Wall Street Zen upgraded shares of HUTCHMED from a "buy" rating to a "strong-buy" rating in a research note on Friday, June 27th. HSBC lowered shares of HUTCHMED from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th.
Check Out Our Latest Report on HCM
HUTCHMED Stock Performance
NASDAQ:HCM traded down $0.17 on Tuesday, reaching $17.61. 8,848 shares of the company's stock were exchanged, compared to its average volume of 85,966. The company has a quick ratio of 2.70, a current ratio of 2.83 and a debt-to-equity ratio of 0.08. The business has a fifty day moving average of $15.50 and a 200-day moving average of $14.87. HUTCHMED has a 52-week low of $11.51 and a 52-week high of $21.50.
Hedge Funds Weigh In On HUTCHMED
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio grew its position in shares of HUTCHMED by 49.6% during the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock worth $39,000 after buying an additional 899 shares in the last quarter. Summit Trail Advisors LLC boosted its holdings in shares of HUTCHMED by 7.7% in the first quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company's stock valued at $212,000 after acquiring an additional 1,004 shares during the period. Barclays PLC lifted its holdings in shares of HUTCHMED by 1,483.6% during the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after purchasing an additional 2,255 shares during the period. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of HUTCHMED by 23.2% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company's stock worth $233,000 after purchasing an additional 2,916 shares during the period. Finally, Crossmark Global Holdings Inc. lifted its holdings in shares of HUTCHMED by 31.4% during the first quarter. Crossmark Global Holdings Inc. now owns 24,420 shares of the company's stock worth $367,000 after purchasing an additional 5,829 shares during the period. 8.82% of the stock is owned by institutional investors and hedge funds.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Stories
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access